On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to European Union Member States.

The European Commission has the option to request an additional 100 million doses. Deliveries were anticipated to start by the end of 2020, subject to clinical success and regulatory authorization.